Medication info
Tradiam Duo Tablet 2.5/500 mg

Tradiam Duo Tablet 2.5/500 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
International Pharmaceutical Co., Ltd.
Appearance
Bright yellow, biconvex, oval film-coated tablet
Packaging
30 tablets/box[(6 tablets/PTP x 5 packs)]
Approval status
Active

MFDS item code 201802631 · Approved 2018.06.26 · Insurance code 643705520

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Switching from linagliptin and metformin combination therapy: Patients switching from linagliptin and metformin combination therapy to this medication should take the same doses of linagliptin and metformin that they were previously taking as the initial dose. 3. Inadequate glycemic control with insulin and metformin combination therapy: The initial dose should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment This medication may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
International Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps improve blood sugar control in patients with type 2 diabetes by using linagliptin and metformin together. It is more effective when combined with dietary control and exercise therapy, contributing to stable management of blood sugar levels. Therefore, this medication is used for blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Switching from linagliptin and metformin combination therapy: Patients switching from linagliptin and metformin combination therapy to this medication should take the same doses of linagliptin and metformin that they were previously taking as the initial dose. 3. Inadequate glycemic control with insulin and metformin combination therapy: The initial dose should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment This medication may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication is primarily used to control blood sugar levels. During the use of this medication, a rare complication called lactic acidosis may occur, so it is essential to check kidney and liver function before taking it. Patients with severely impaired kidney function or liver function problems, as well as those with acute illness or dehydration, should not take this medication. Additionally, it is not administered to patients with type 1 diabetes or those suffering from diabetic ketoacidosis or diabetic pre-coma. It is also recommended that pregnant or breastfeeding women refrain from using this medication. This medication may cause hypoglycemia, so blood sugar must be monitored closely, especially when taken with insulin or sulfonylureas. It is important to regularly check kidney function during the use of this medication to ensure no abnormalities occur. Acute pancreatitis or skin blistering disorders may appear, so if there are continuous abdominal pain or skin abnormalities, consult a doctor immediately. The risk of lactic acidosis increases when this medication is taken with alcohol, so alcohol consumption should be avoided. Additionally, during the use of this medication, it may be necessary to temporarily interrupt drug use before and after certain radiological tests. In elderly patients, the decline in kidney function is common, so kidney function should be monitored more closely during the use of this medication. The safety and efficacy of this medication have not been established in children, so it is not recommended for children under 10 years of age. If any unusual symptoms or discomfort occur during the use of the medication, it is important to consult a medical professional immediately.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 107 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesiculobullous pemphigoid
  • joint pain with severe and disability
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • septicemia
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • itching
  • insomnia
  • depression
  • hypertension
  • benign prostatic hyperplasia
  • angina
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • stomatitis
  • mediastinitis
  • pneumonia
  • rhinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • dizziness
  • drowsiness
  • chest discomfort
  • asthenia
  • pain
  • nosebleed
  • oropharyngeal pain
  • voice disorder
  • epistaxis
  • hearing loss
  • erectile dysfunction
  • thyroid goiter
  • confused state
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, preferably at room temperature between 1°C and 30°C. This storage helps maintain the medication's effectiveness and prevents degradation.

Appearance and packaging

Appearance

Bright yellow, biconvex, oval film-coated tablet

Package unit

30 tablets/box[(6 tablets/PTP x 5 packs)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.